Ema, an authorization request has been received for anti-Covid MSD

Rome, 25 November – EMA receives marketing authorization (Aic) application for molnupiravir (Lagevrio), the antiviral pill for the treatment of Covid-19 in adults, developed by Merck Sharp & Dohme (Msd, Merck in the US and Canada) in collaboration with Ridgeback Biotherapeutics.